Compare Aventis Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs LUPIN - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA LUPIN SANOFI INDIA/
LUPIN
 
P/E (TTM) x 40.9 108.0 37.9% View Chart
P/BV x 7.2 2.5 292.3% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 SANOFI INDIA   LUPIN
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
LUPIN
Mar-19
SANOFI INDIA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs6,840986 693.7%   
Low Rs4,630720 642.7%   
Sales per share (Unadj.) Rs1,203.1369.5 325.6%  
Earnings per share (Unadj.) Rs165.313.4 1,232.9%  
Cash flow per share (Unadj.) Rs209.937.4 561.4%  
Dividends per share (Unadj.) Rs84.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs963.6303.7 317.3%  
Shares outstanding (eoy) m23.03452.49 5.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.82.3 206.4%   
Avg P/E ratio x34.763.6 54.5%  
P/CF ratio (eoy) x27.322.8 119.7%  
Price / Book Value ratio x6.02.8 211.9%  
Dividend payout %50.80-   
Avg Mkt Cap Rs m132,078386,064 34.2%   
No. of employees `0003.317.7 18.7%   
Total wages/salary Rs m4,06831,513 12.9%   
Avg. sales/employee Rs Th8,393.89,453.8 88.8%   
Avg. wages/employee Rs Th1,232.41,782.0 69.2%   
Avg. net profit/employee Rs Th1,153.0343.0 336.2%   
INCOME DATA
Net Sales Rs m27,708167,182 16.6%  
Other income Rs m8973,640 24.6%   
Total revenues Rs m28,605170,822 16.7%   
Gross profit Rs m6,23528,822 21.6%  
Depreciation Rs m1,02710,850 9.5%   
Interest Rs m73,078 0.2%   
Profit before tax Rs m6,09818,534 32.9%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m2,2929,017 25.4%   
Profit after tax Rs m3,8066,066 62.7%  
Gross profit margin %22.517.2 130.5%  
Effective tax rate %37.648.7 77.3%   
Net profit margin %13.73.6 378.6%  
BALANCE SHEET DATA
Current assets Rs m15,922138,536 11.5%   
Current liabilities Rs m6,23561,299 10.2%   
Net working cap to sales %35.046.2 75.7%  
Current ratio x2.62.3 113.0%  
Inventory Days Days6484 76.0%  
Debtors Days Days21112 18.6%  
Net fixed assets Rs m7,539127,516 5.9%   
Share capital Rs m230905 25.4%   
"Free" reserves Rs m21,962136,517 16.1%   
Net worth Rs m22,192137,422 16.1%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m29,839279,494 10.7%  
Interest coverage x872.17.0 12,422.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.6 155.2%   
Return on assets %12.83.3 390.6%  
Return on equity %17.24.4 388.6%  
Return on capital %27.58.9 308.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58759,414 12.8%   
Fx outflow Rs m7,14522,282 32.1%   
Net fx Rs m44237,132 1.2%   
CASH FLOW
From Operations Rs m3,73916,660 22.4%  
From Investments Rs m-731-32,825 2.2%  
From Financial Activity Rs m-1,9727,441 -26.5%  
Net Cashflow Rs m1,036-8,724 -11.9%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 60.4 0.2 30,200.0%  
Indian inst/Mut Fund % 14.4 11.3 127.4%  
FIIs % 14.6 31.9 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   15,184 98,259 15.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Up; Telecom Stocks Rally(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.6% while the Hang Seng is up 0.9%.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Nov 19, 2019 10:31 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - STERLING BIOTECH COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS